Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

12.48 +0.10 (+0.81%)
Streaming Delayed Price Updated: 9:34 AM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Felicia Williams Joins NeoGenomics Board of Directors
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Reports Third Quarter 2024 Results
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Reports Third Quarter 2023 Results
Via ACCESSWIRE
News headline image
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Reports Second Quarter 2024 Results
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024
From NeoGenomics, Inc.
Via Business Wire
News headline image
Fort Myers’ Mayor to Proclaim June as NeoGenomics’ Commitment to Cancer Month
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Reports First Quarter 2024 Results
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Announces Senior Leadership Promotions
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
From NeoGenomics, Inc.
Via Business Wire
News headline image
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
ROSEN, A LEADING NATIONAL FIRM, Encourages NeoGenomics, Inc. Investors to Inquire About Securities Class Action Investigation – NEO
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
News headline image
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
From FN Media Group LLC
Via GlobeNewswire
News headline image
NeoGenomics to Appeal Ruling
Via ACCESSWIRE
News headline image
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
Via ACCESSWIRE
News headline image
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.